Rivas Capital

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Comgy GmbH, founded in 2017 and based in Berlin, Germany, specializes in digital metering solutions for the housing and energy sectors. The company offers a range of products including a sub-metering solution that enables users to efficiently read meters, alongside sensors and smoke alarms. Comgy provides a Meter Gateway Management application, which acts as a control center for remote device configuration and data processing, as well as a Meter Installation Manager application for the digital registration of radiator measurements, supported by photographic documentation. Additionally, its Polyglot gateway facilitates encrypted communication between meters, sensors, and its customer platform. Comgy's technology enhances the measurement, visualization, and billing processes of heat, water, and electricity consumption in real estate, promoting transparency and facilitating energy savings.

Inari is a biotechnology company focused on transforming agriculture to positively impact society and the environment. By emphasizing diversity in its operations, Inari fosters innovation aimed at developing a new food system. The company utilizes advanced technology, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its distinctive SEEDesign platform enables the enhancement of various crops tailored to specific geographic conditions, facilitating the creation of innovative agricultural products with clear market strategies.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

Regenacy Pharmaceuticals, LLC is a biopharmaceutical company based in Boston, Massachusetts, founded in 2016. The company focuses on developing innovative treatments for peripheral neuropathies, hemoglobinopathies, and certain oncology indications. Its approach centers on the regeneration of normal protein function through the use of oral, isoform-selective histone deacetylase (HDAC) inhibitors. Notably, Regenacy is advancing the selective HDAC6 inhibitor ricolinostat, which has potential applications in treating sickle cell disease and beta-thalassemia. Through its novel, disease-modifying strategies, Regenacy aims to address significant unmet medical needs in these therapeutic areas.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. The company's leading candidate, KSI-301, is a vascular endothelial growth factor (VEGF)-biological agent currently undergoing Phase 1b clinical trials for the treatment of wet age-related macular degeneration and diabetic retinopathy. Additionally, Kodiak is advancing KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate aimed at addressing inflammation and abnormal blood vessel growth associated with retinal vascular diseases, which is in the preclinical stage. The company's early research pipeline also includes KSI-601, a triplet inhibitor targeting dry AMD. Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences was previously known as Oligasis, LLC before its name change in 2015.

ReviveMed Inc is a precision-medicine company based in Cambridge, Massachusetts, founded in 2016. It specializes in a platform that utilizes data from small molecules or metabolites to derive actionable insights. The company's technology employs a network-based machine learning algorithm for the integrative analysis of untargeted metabolomic data alongside large-scale molecular information, which includes data from genes, proteins, drugs, and diseases. This innovative approach enables researchers to develop in-house therapeutics specifically targeting patients with liver diseases and related conditions, thereby aiming to improve health outcomes through the unlocking of metabolomic data's potential.

GreenLight Biosciences, Inc. is a biotechnology company that specializes in developing RNA-based solutions for agricultural and pharmaceutical applications. Headquartered in Medford, Massachusetts, with an additional facility in North Carolina, the company focuses on producing high-quality RNA quickly and cost-effectively. GreenLight's technology platform facilitates the biological conversion of renewable substrates into valuable products, including chemicals and fuels. The company is actively involved in advancing vaccine development, particularly mRNA-based candidates aimed at preventing diseases such as SARS-CoV-2. Additionally, GreenLight engages in crop management and plant protection initiatives, contributing to sustainable agricultural practices and supporting the health of pollinators. Through its innovative approaches, GreenLight Biosciences aims to address global challenges in food security and public health.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.

Gamalon, Inc. specializes in statistical machine learning solutions, focusing on Bayesian probabilistic programming languages. Founded in 2013 and based in Boston, Massachusetts, the company has developed an AI-driven machine intelligence technology that automates the writing and rewriting of its own Bayesian programs. This innovation allows businesses to convert unstructured text into structured data efficiently, enabling e-commerce and manufacturing sectors to train their systems with minimal data while achieving accuracy comparable to extensively trained neural networks. Additionally, Gamalon offers a conversational machine intelligence platform that interprets and summarizes customer messages, facilitating data-driven decision-making and enhancing customer experience.

Force of Nature manufactures electronic appliances designed to create a cleaning solution using basic ingredients found at home.

N12 Technologies, Inc. specializes in the manufacturing and supply of advanced nano-composite materials aimed at enhancing the performance of composite products in various industries, including aerospace, automotive, and consumer goods. The company offers innovative solutions such as NanoStitch, which reinforces the interlaminar region during composite lay-up, and the Surface Layer System, which improves thermal and electrical conductivity for applications like surface curing and deicing. Utilizing technology licensed from MIT, N12 produces vertically-aligned carbon nanotube forests that enhance shear strength, fatigue life, and impact resistance while preventing crack growth and delamination. Founded in 2012 and headquartered in Somerville, Massachusetts, N12 Technologies aims to provide cost-effective, high-performance materials that seamlessly integrate into existing fabrication processes without requiring modifications.

Zipline Inc. is a California-based company that specializes in designing, manufacturing, and operating drones for the delivery of essential medical supplies, including vaccines, medicines, and blood. Founded in 2011 and headquartered in Half Moon Bay, the company aims to provide instant access to vital medical products for every individual globally. Since its inception, Zipline has developed a rapid delivery drone and an autonomous logistics network, allowing for efficient distribution to hospitals and health centers, particularly in remote areas. By leveraging its proprietary fixed-wing drone technology, Zipline facilitates timely deliveries that support the medical community and enhance patient care.

Aircuity, Inc. specializes in intelligent measurement solutions aimed at enhancing energy efficiency and indoor environmental quality in various settings, including commercial offices, educational institutions, healthcare facilities, and public venues. The company offers a range of products, including the Sensor Suite, which supports multipoint environmental sampling, and various sensors and probes designed for specific monitoring tasks, such as temperature and air quality. Their technology enables demand-controlled ventilation, allowing buildings to optimize energy use while maintaining safe and comfortable environments. Founded in 2000 and headquartered in Newton, Massachusetts, Aircuity markets its solutions across multiple international regions, reinforcing its commitment to improving indoor air quality and operational efficiency.

N12 Technologies, Inc. specializes in the manufacturing and supply of advanced nano-composite materials aimed at enhancing the performance of composite products in various industries, including aerospace, automotive, and consumer goods. The company offers innovative solutions such as NanoStitch, which reinforces the interlaminar region during composite lay-up, and the Surface Layer System, which improves thermal and electrical conductivity for applications like surface curing and deicing. Utilizing technology licensed from MIT, N12 produces vertically-aligned carbon nanotube forests that enhance shear strength, fatigue life, and impact resistance while preventing crack growth and delamination. Founded in 2012 and headquartered in Somerville, Massachusetts, N12 Technologies aims to provide cost-effective, high-performance materials that seamlessly integrate into existing fabrication processes without requiring modifications.

Lumicell, Inc. specializes in developing image-guided cancer surgery solutions aimed at enhancing surgical outcomes for patients with various types of cancer, including breast cancer and sarcoma. The company has created an intraoperative imaging system that utilizes a handheld device in conjunction with a cancer-specific optical contrast agent. This system provides real-time visual feedback on the presence of residual cancer cells within the tumor bed, allowing surgeons to effectively remove any remaining cancerous tissue during the procedure. By illuminating cancer cells, Lumicell's technology aims to minimize the need for repeat surgeries due to positive margins and local recurrence, thereby improving patient outcomes. The company is also exploring applications of its technology in other cancers, such as colorectal cancer and pancreatic cancer. Founded in 2008 and based in Wellesley, Massachusetts, Lumicell continues to advance its clinical investigations to validate the effectiveness and safety of its innovative surgical solutions.